Relay passes on the lirafugratinib baton
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
